Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy E Moran

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Trends in Cancer|May 12, 2023
Thymic expression of immune checkpoint molecules and their implication for response to immunotherapiesBreanna Caruso, Amy E Moran
Immunology|December 21, 2011
T-cell receptor affinity in thymic developmentAmy E Moran, Kristin A Hogquist
Nature Immunology|May 19, 2009
Treg cells meet their limitKristin A Hogquist, Amy E Moran
Oncology (Williston Park, N.Y.)|March 27, 2020
The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate CancerAshray Maniar, Amy E Moran, Julie N Graff
Cancer Immunology Research|December 20, 2018
Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 AgonistFanny Polesso, Andrew D Weinberg, Amy E Moran
Journal of Immunology (Baltimore, Md. : 1950)|August 10, 2016
Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In SituAmy E Moran, Fanny Polesso, Andrew D Weinberg
Current Opinion in Immunology|February 19, 2013
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapyAmy E Moran, Magdalena Kovacsovics-Bankowski, Andrew D Weinberg
Annals of Translational Medicine|December 30, 2017
Predictors of response and resistance to checkpoint inhibitors in solid tumorsSanjana V Rao, Amy E Moran, Julie N Graff
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2022
Restored Thymic Output after Androgen Blockade Participates in Antitumor ImmunityFanny Polesso, Breanna Caruso, Scott A Hammond, et al.
Immunohorizons|March 29, 2024
PD-1 Limits IL-2 Production and Thymic Regulatory T Cell DevelopmentBreanna Caruso, Benjamin R Weeder, Reid F Thompson, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Trends in Cancer|May 12, 2023
Thymic expression of immune checkpoint molecules and their implication for response to immunotherapiesBreanna Caruso, Amy E Moran
Immunology|December 21, 2011
T-cell receptor affinity in thymic developmentAmy E Moran, Kristin A Hogquist
Nature Immunology|May 19, 2009
Treg cells meet their limitKristin A Hogquist, Amy E Moran
Oncology (Williston Park, N.Y.)|March 27, 2020
The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate CancerAshray Maniar, Amy E Moran, Julie N Graff
Cancer Immunology Research|December 20, 2018
Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 AgonistFanny Polesso, Andrew D Weinberg, Amy E Moran
Journal of Immunology (Baltimore, Md. : 1950)|August 10, 2016
Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In SituAmy E Moran, Fanny Polesso, Andrew D Weinberg
Current Opinion in Immunology|February 19, 2013
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapyAmy E Moran, Magdalena Kovacsovics-Bankowski, Andrew D Weinberg
Annals of Translational Medicine|December 30, 2017
Predictors of response and resistance to checkpoint inhibitors in solid tumorsSanjana V Rao, Amy E Moran, Julie N Graff
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2022
Restored Thymic Output after Androgen Blockade Participates in Antitumor ImmunityFanny Polesso, Breanna Caruso, Scott A Hammond, et al.
Immunohorizons|March 29, 2024
PD-1 Limits IL-2 Production and Thymic Regulatory T Cell DevelopmentBreanna Caruso, Benjamin R Weeder, Reid F Thompson, et al.
Pageof 4